However, it is currently unknown if Glo-1 activity is altered in transgenic mouse models of AD and whether ψ-GSH treatment can reverse the Glo-1 deficits as well as oxidative stress in aged APP/PS1 mouse model of AD. This evidence concerns the gene GLO1 and Alzheimer disease.